Skip to main content

Table 1 Baseline characteristics of the SWEFOT participants for all patients and also within each treatment group

From: Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial

  All SWEFOT patients (N = 487) All study patients (N = 159) MTX responders (N = 49) Triple therapy (N = 55) Combination MTX + INF (N = 55) p-value
Disease duration, months 6.16 (3.20) 6.08 (3.20) 5.86 (3.12) 6.00 (3.10) 6.35 (3.40) 0.79
Sex, female 70.6 (344) 72.3 (115) 63.3 (31) 74.5 (41) 78.2 (43) 0.21
ACPA pos.% (n) 63.7 (310) 60.3 (91) 55.6 (25) 62.3 (33) 62.3 (33) 0.74
RF pos.% (n) 68.4 (333) 69.1 (96) 68.2 (30) 71.4 (35) 67.4 (31) 0.90
DAS 28 5.73 (1.01) 5.70 (1.00) 5.23 (0.99) 5.99 (1.02) 5.85 (0.92) <0.001*/0.004**/1.0^
ESR (mm) 39.8 (28.1) 38.6 (26.6) 31.2 (24.4) 49.3 (27.7) 34.4 (24.3) 0.001*/1.0**/0.008^
CRP (mg/L) 33.7 (42.4) 35.1 (40.4) 27.3 (40.1) 47.1 (41.2) 29.8 (37.7) 0.04*/1.0**/0.07^
HAQ 1.19 (0.58) 1.19 (0.59) 0.97 (0.47) 1.35 (0.65) 1.25 (0.57) 0.003*/0.04**/1.0^
T-SHS 4.54 (8.01) 4.79 (7.85) 3.04 (6.00) 5.98 (8.53) 5.08 (8.37) 0.07
ES 1.91 (3.75) 1.99 (3.56) 1.71 (2.87) 2.43 (4.32) 1.76 (3.21) 0.52
DXR-BMD (g/cm2) ---- 0.58 (0.08) 0.59 (0.08) 0.57 (0.06) 0.56 (0.08) 0.14
  1. The values are mean (SD) or percentages (%).
  2. *Between MTX-responders and triple therapy.
  3. ** Between MTX-responders and combination MTX + INF.
  4. ^ Between triple therapy and combination MTX + INF.
  5. Abbreviation: ACPA: Anti-citrullinated protein antibody, RF: Rheumatoid factor, DAS28: 28 joint-based disease activity score, ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, HAQ: Health assessment questionnaire disability index, T-SHS: Total van der Heijde modified Sharp score, ES: Erosion Score, DXR: Digital X-ray radiogrammetry, BMD: Bone mineral density.